<DOC>
	<DOCNO>NCT01728116</DOCNO>
	<brief_summary>To determine EndoBarrier safely effectively improve glycemic control obese subject type 2 diabetes</brief_summary>
	<brief_title>Safety Efficacy EndoBarrier Subjects With Type 2 Diabetes Who Are Obese</brief_title>
	<detailed_description>This randomize , double blind , prospective study . Subjects evaluate randomize either device sham treatment group qualify study . A comparison glycemic control two group assess primary outcome measurement well safety profile device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Males/females age ≥ 21 year ≤ 65 year Diagnosis Type 2 Diabetes ≤ 20 year Obese individual ( BMI ≥ 30 kg/m2 ≤ 55 kg/m2 ) Stable dos ( least 3 month ) two antiT2DM medication ( MET , SU , DPP4i TZD ) Glycemic state : HbA1c screen ≥ 7.5 % ≤ 10.0 % . Subjects willing comply study requirement Subjects sign informed consent form Diagnosis type 1 diabetes mellitus history ketoacidosis Cpeptide &lt; 1.0 ng/mL Triglyceride level &gt; 400 mg/dL Vitamin D deficiency ( &lt; 20 ng/mL ) Male subject serum Creatinine &gt; 1.5 mg/dl female subject Creatinine &gt; 1.4 mg/dL Uncorrectable bleeding diathesis , platelet dysfunction , thrombocytopenia platelet count less 100,000/microliter , know coagulopathy Height &lt; 5 foot ( 152.4 cm ) Current alcohol drug addiction Symptomatic kidney stone gallstone within 6 month prior randomization Chronic pancreatitis acute pancreatitis within 12 month randomization Diagnosis osteoporosis currently take bisphosphonates teriparatide Diagnosis autoimmune connective tissue disorder ( e.g. , lupus erythematosus , scleroderma ) Active gastroesophageal reflux disease [ GERD ] uncontrolled Proton Pump Inhibitor ( PPI ) Thyroid disease unless control medication Currently take NonSteroidal AntiInflammatory Drugs [ NSAIDs ] ( e.g. , aspirin , ibuprofen , etc . ) within 10 day prior randomization and/or need expect use agent trial 12 month post index procedure Currently take prescription antithrombotic therapy ( e.g. , anticoagulant antiplatelet agent ) within 10 day prior randomization and/or need expect need use trial 12 month post index procedure Currently take systemic corticosteroid , drug know affect GI motility , prescription/overthecounter weight loss medication , medication know cause significant weight gain weight loss within 30 day prior randomization and/or need expect need use medication trial 12 month post index procedure Medication type 2 diabetes MET , SU , DPP4i , TZD ( e.g. , GLP1 insulin ) within 3 month screen Chronic use narcotic , opiate , benzodiazepine , addictive tranquilizer Allergy hypersensitivity ceftriaxone , cephalosporin , penicillin , equivalent antibiotic Active Helicobacter pylorus infection ( Note : Subjects may eligible undergo 2 week antibiotic treatment without rescreening ) Previous GI surgery abnormal GI anatomical finding could preclude ability place EndoBarrier device , liner affect function liner Abnormal pathology condition gastrointestinal tract , include current ulcer Crohn 's disease , history atresia untreated stenosis , current upper gastrointestinal bleeding condition within 3 month randomization Any condition major illness place subject undue risk participate study Poor dentition allow complete chew food Enrolled another investigational study within 3 month screen study ( Enrollment observational study permit ) Residing location without ready access study site medical resource Documented weight loss &gt; 10 pound anytime 3 month precede randomization Positive stool guaiac time screen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>glycemic control , type 2 diabetes , device , obese</keyword>
</DOC>